[1] CHEUNG C C, NATTEL S, MACLE L, et al.Management of Atrial Fibrillation in 2021:An Updated Comparison of the Current CCS/CHRS, ESC, and AHA/ACC/HRS Guidelines[J].Can J Cardiol, 2021, 37(10):1607-1618.
[2] CARLISLE M A, FUDIM M, DEVORE A D, et al.Heart failure and atrial fibrillation, like fire and fury[J].JACC Heart Fail, 2019, 7(6):447-456.
[3] CHEW D S, BLACK-MAIER E, LORING Z, et al.Diagnosis-to-ablation time and recurrence of atrial fibrillation following catheter ablation:a systematic review and meta-analysis of observational studies[J].Circ Arrhythm Electrophysiol, 2020, 13(4):e008128.
[4] BEGG G A, SWOBODA P P, KARIM R, et al.Imaging, biomarker and invasive assessment of diffuse left ventricular myocardial fibrosis in atrial fibrillation[J].J Cardiovasc Magn Reson, 2020, 22(1):13.
[5] VIANELLO E, DOZIO E, TACCHINI L, et al.ST2/IL-33 signaling in cardiac fibrosis[J].Int J Biochem Cell Biol, 2019, 116:105619.
[6] MA X, YUAN H, LUAN H X, et al.Elevated soluble ST2 concentration may involve in the progression of atrial fibrillation[J].Clin Chim Acta, 2018, 480:138-142.
[7] MUJOVI N, MARINKOVI M, LENARCZYK R, et al.Catheter ablation of atrial fibrillation:an overview for clinicians[J].Adv Ther, 2017, 34(8):1897-1917.
[8] MATEI L L, SILIŞTE C, STOICA S, et al.Predictors of atrial fibrillation recurrences after a first radiofrequency catheter ablation intervention for paroxysmal atrial fibrillation-experience of a low volume ablation centre[J].Medicina(Kaunas), 2021, 57(11):1139.
[9] STEINBERG C, CHAMPAGNE J, DEYELL M W, et al.Prevalence and outcome of early recurrence of atrial tachyarrhythmias in the Cryoballoon vs Irrigated Radiofrequency Catheter Ablation(CIRCA-DOSE) study[J].Heart Rhythm, 2021, 18(9):1463-1470.
[10] EVERETT T H, LI H, MANGRUM J M, et al.Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation[J].Circulation, 2000, 102(12):1454-1460.
[11] KORODI S, TOGANEL R, BENEDEK T, et al.Impact of inflammation-mediated myocardial fibrosis on the risk of recurrence after successful ablation of atrial fibrillation-the FIBRO-RISK study:Protocol for a non-randomized clinical trial[J].Medicine(Baltimore), 2019, 98(9):e14504.
[12] CHEN J, ARENTZ T, COCHET H, et al.Extent and spatial distribution of left atrial arrhythmogenic sites, late gadolinium enhancement at magnetic resonance imaging, and low-voltage areas in patients with persistent atrial fibrillation:comparison of imaging vs. electrical parameters of fibrosis and arrhythmogenesis[J].Europace, 2019, 21(10):1484-1493.
[13] OKAR S, KAYPAKLI O, ŞAHIN D Y, et al.Fibrosis marker soluble ST2 predicts atrial fibrillation recurrence after cryoballoon catheter ablation of nonvalvular paroxysmal atrial fibrillation[J].Korean Circ J, 2018, 48(10):920-929.
[14] DE LA FUENTE M, MACDONALD T T, HERMOSO M A.The IL-33/ST2 axis:Role in health and disease[J].Cytokine Growth Factor Rev, 2015, 26(6):615-623.
[15] ALTARA R, GHALI R, MALLAT Z, et al.Conflicting vascular and metabolic impact of the IL-33/sST2 axis[J].Cardiovasc Res, 2018, 114(12):1578-1594.
[16] KOTSIOU O S, GOURGOULIANIS K I, ZAROGIANNIS S G.IL-33/ST2 axis in organ fibrosis[J].Front Immunol, 2018, 9:2432.
[17] DEMYANETS S, KAUN C, PENTZ R, et al.Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature[J].J Mol Cell Cardiol, 2013, 60:16-26.
[18] FRIÕES F, LOURENÇO P, LASZCZYNSKA O, et al.Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction[J].Clin Res Cardiol, 2015, 104(6):491-499.
[19] DZESHKA M S, LIP G Y, SNEZHITSKIY V, et al.Cardiac fibrosis in patients with atrial fibrillation:mechanisms and clinical implications[J].J Am Coll Cardiol, 2015, 66(8):943-959.
[20] BEYER C, TOKARSKA L, STVHLINGER M, et al.Structural cardiac remodeling in atrial fibrillation[J].JACC Cardiovasc Imaging, 2021, 14(11):2199-2208.
[21] PASCUAL-FIGAL D A, LAX A, PEREZ-MARTINEZ M T, et al.Clinical relevance of sST2 in cardiac diseases[J].Clin Chem Lab Med, 2016, 54(1):29-35.
[22] MATILLA L, IBARROLA J, ARRIETA V, et al.In vitro soluble ST2 promotes oxidative stress and inflammation in cardiac fibroblasts:an study in aortic stenosis[J].Clin Sci(Lond), 2019, 133(14):1537-1548.
[23] LIU M, MAO C, LI J, et al.Effects of the activin a-follistatin system on myocardial cell apoptosis through the endoplasmic reticulum stress pathway in heart failure[J].Int J Mol Sci, 2017, 18(2):374.
[24] AOYAMA M, KAWASE H, BANDO Y K, et al.Dipeptidyl peptidase 4 inhibition alleviates shortage of circulating glucagon-like peptide-1 in heart failure and mitigates myocardial remodeling and apoptosis via the exchange protein directly activated by cyclic AMP 1/Ras-related protein 1 axis[J].Circ Heart Fail, 2016, 9(1):e002081.
[25] KORANTZOPOULOS P, LETSAS K, FRAGAKIS N, et al.Oxidative stress and atrial fibrillation:an update[J].Free Radic Res, 2018, 52(11):1199-1209.
[26] SHAH A K, BHULLAR S K, ELIMBAN V, et al.Oxidative stress as a mechanism for functional alterations in cardiac hypertrophy and heart failure[J].Antioxidants(Basel), 2021, 10(6):931.
[27] SPINALE F G, JANICKI J S, ZILE M R.Membrane-associated matrix proteolysis and heart failure[J].Circ Res, 2013, 112(1):195-208.
[28] MUKHERJEE R, AKAR J G, WHARTON J M, et al.Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion[J].J Cardiovasc Transl Res, 2013, 6(4):528-535.
[29] CHEN C, QU X, GAO Z, et al.Soluble ST2 in patients with nonvalvular atrial fibrillation and prediction of heart failure[J].Int Heart J, 2018, 9(1):58-63.
[30] JIA Q, HAN W, SHI S, et al.The effects of ACEI/ARB, aldosterone receptor antagonists and statins on preventing recurrence of atrial fibrillation:a protocol for systematic review and network meta-analysis[J].Medicine(Baltimore), 2021, 100(1):e24280.
[31] LYU S Q, YANG Y M, ZHU J, et al.Effects of angiotensin-converting enzyme inhibitor and angiotensin Ⅱ receptor blocker on one-year outcomes of patients with atrial fibrillation:insights from a multicenter registry study in China[J].J Geriatr Cardiol, 2020, 17(12):750-758.
[32] LI L Y, LOU Q, LIU G Z, et al.Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation[J].Eur J Pharmacol, 2020, 881:173120. |
